EU’s Biotech Act Draft Lacks ‘Competition-Driven’ Biosimilar Policies, Warns Medicines For Europe

The Second Part Of The Act Is Expected In 2026

 
• By Urtė Fultinavičiūtė
  
A person standing on a question mark
(Shutterstock)

More from Regulation

More from Policy & Regulation